BACKGROUND: Coronary artery disease (CAD) was the second leading cause of death for the past 3 years in Taiwan. The insulin-like growth factor (IGF) system is considered a new risk factor of CAD because investigations show that the levels and bioactivity of IGF-I and IGFBP-3 (where IGFBP is insulin-like growth factor-binding protein) may be involved in elevating the risk of CAD. This study investigated the relationships among IGF-I +1770, IGF-I +6093, and IGFBP-3 -202 genetic polymorphisms and CAD in the Taiwanese population. METHODS: A total of 581 subjects, including 390 non-CAD controls and 191 patients with CAD, were recruited and the isolated DNA was subjected to real-time polymerase chain to evaluate the effects of these three polymorphic variants on CAD. RESULTS: Our results showed a significant association between the IGF-I +1770 gene polymorphism and increased risk of CAD. Furthermore, CAD patients with a minimum of one mutant C allele, T/C or C/C, in IGF-I +1770 gene polymorphism had significantly high blood pressure including systolic blood pressure (SBP; P = 0.025) and diastolic blood pressure (DBP; P = 0.004), compared to CAD patients with T/T homozygotes. Moreover, CAD patients with a minimum of one mutant A allele, G/A or A/A, in the IGF-I +6093 gene polymorphism had a 1.695-fold elevated risk of congestive heart failure (CHF), compared to CAD patients with the G/G homozygote. CONCLUSIONS: Polymorphism of IGF-I +1770 was associated with increased CAD risk. In CAD patients, the contributions of IGF-I +1770 and +6093 could be through the effect on blood pressure in CAD patients.
BACKGROUND:Coronary artery disease (CAD) was the second leading cause of death for the past 3 years in Taiwan. The insulin-like growth factor (IGF) system is considered a new risk factor of CAD because investigations show that the levels and bioactivity of IGF-I and IGFBP-3 (where IGFBP is insulin-like growth factor-binding protein) may be involved in elevating the risk of CAD. This study investigated the relationships among IGF-I +1770, IGF-I +6093, and IGFBP-3 -202 genetic polymorphisms and CAD in the Taiwanese population. METHODS: A total of 581 subjects, including 390 non-CAD controls and 191 patients with CAD, were recruited and the isolated DNA was subjected to real-time polymerase chain to evaluate the effects of these three polymorphic variants on CAD. RESULTS: Our results showed a significant association between the IGF-I +1770 gene polymorphism and increased risk of CAD. Furthermore, CAD patients with a minimum of one mutant C allele, T/C or C/C, in IGF-I +1770 gene polymorphism had significantly high blood pressure including systolic blood pressure (SBP; P = 0.025) and diastolic blood pressure (DBP; P = 0.004), compared to CAD patients with T/T homozygotes. Moreover, CAD patients with a minimum of one mutant A allele, G/A or A/A, in the IGF-I +6093 gene polymorphism had a 1.695-fold elevated risk of congestive heart failure (CHF), compared to CAD patients with the G/G homozygote. CONCLUSIONS: Polymorphism of IGF-I +1770 was associated with increased CAD risk. In CAD patients, the contributions of IGF-I +1770 and +6093 could be through the effect on blood pressure in CAD patients.
Authors: Ingrid Rietveld; Joop A M J L Janssen; Albert Hofman; Huibert A P Pols; Cornelia M van Duijn; Steven W J Lamberts Journal: Eur J Endocrinol Date: 2003-02 Impact factor: 6.664
Authors: Mojgan Yazdanpanah; Ingrid Rietveld; Joop A M J L Janssen; Omer T Njajou; Albert Hofman; Theo Stijnen; Huibert A P Pols; Steven W J Lamberts; Jacqueline C M Witteman; Cornelia M van Duijn Journal: Am J Cardiol Date: 2006-03-10 Impact factor: 2.778
Authors: A W van den Beld; M L Bots; J A M L L Janssen; H A P Pols; S W J Lamberts; D E Grobbee Journal: Am J Epidemiol Date: 2003-01-01 Impact factor: 4.897
Authors: T Norat; L Dossus; S Rinaldi; K Overvad; H Grønbaek; A Tjønneland; A Olsen; F Clavel-Chapelon; M C Boutron-Ruault; H Boeing; P H Lahmann; J Linseisen; G Nagel; A Trichopoulou; D Trichopoulos; V Kalapothaki; S Sieri; D Palli; S Panico; R Tumino; C Sacerdote; H B Bueno-de-Mesquita; P H M Peeters; C H van Gils; A Agudo; P Amiano; E Ardanoz; C Martinez; R Quirós; M J Tormo; S Bingham; T J Key; N E Allen; P Ferrari; N Slimani; E Riboli; R Kaaks Journal: Eur J Clin Nutr Date: 2006-08-09 Impact factor: 4.016